Table of Contents
Fibrates are a class of medications primarily used to treat hyperlipidemia, especially elevated triglyceride levels. Understanding their pharmacokinetics is crucial for optimizing their therapeutic effects and minimizing side effects.
Absorption of Fibrates
Fibrates are typically administered orally. Their absorption can vary depending on the specific compound and formulation. For example, fenofibrate is usually taken with food to enhance absorption, as fat intake stimulates bile secretion, aiding in the solubilization of the drug.
The bioavailability of fibrates ranges from approximately 20% to 60%. Factors such as gastrointestinal pH, motility, and the presence of food influence the extent and rate of absorption.
Metabolism of Fibrates
Once absorbed, fibrates undergo extensive hepatic metabolism. Fenofibrate, for instance, is hydrolyzed in the liver to its active form, fenofibric acid. This active metabolite is responsible for most of the pharmacological activity.
Metabolism involves conjugation with glucuronic acid, facilitating renal excretion. The metabolic pathways ensure that fibrates are effectively processed and prepared for elimination.
Excretion of Fibrates
Fibrates are primarily eliminated through the kidneys. The majority of the drug and its metabolites are excreted in the urine. The excretion rate influences the dosing interval and is affected by renal function.
In patients with impaired renal function, the clearance of fibrates decreases, necessitating dosage adjustments to prevent accumulation and toxicity.
Summary of Pharmacokinetic Phases
- Absorption: Oral administration, enhanced by food, with variable bioavailability.
- Metabolism: Hepatic hydrolysis and conjugation, producing active metabolites.
- Excretion: Renal elimination of unchanged drug and metabolites, requiring dose adjustment in renal impairment.
Understanding these pharmacokinetic principles helps clinicians optimize fibrate therapy, ensuring maximum efficacy while minimizing adverse effects.